Sutro, Sanofi to jointly produce two vaccine candidates
Sanofi Pasteur is expected to leverage Sutro’s cell-free protein synthesis technology in the production of two vaccine candidates. Sutro Biopharma chief executive officer William Newell said the collaboration
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.